EA202090718A1 - Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1) - Google Patents
Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1)Info
- Publication number
- EA202090718A1 EA202090718A1 EA202090718A EA202090718A EA202090718A1 EA 202090718 A1 EA202090718 A1 EA 202090718A1 EA 202090718 A EA202090718 A EA 202090718A EA 202090718 A EA202090718 A EA 202090718A EA 202090718 A1 EA202090718 A1 EA 202090718A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibody
- antigen binding
- binding site
- binds
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558510P | 2017-09-14 | 2017-09-14 | |
| PCT/US2018/050916 WO2019055677A1 (en) | 2017-09-14 | 2018-09-13 | NKG2D, CD16, AND LIQUID-LIKE MOLECULE-1-LIKE PROTEINS (CLL-1) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202090718A1 true EA202090718A1 (ru) | 2020-07-01 |
Family
ID=65723086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202090718A EA202090718A1 (ru) | 2017-09-14 | 2018-09-13 | Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1) |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200277384A1 (https=) |
| EP (1) | EP3681532A4 (https=) |
| JP (2) | JP2020534269A (https=) |
| KR (1) | KR20200051789A (https=) |
| CN (1) | CN111432832A (https=) |
| AU (1) | AU2018331412A1 (https=) |
| BR (1) | BR112020005078A2 (https=) |
| CA (1) | CA3075857A1 (https=) |
| EA (1) | EA202090718A1 (https=) |
| IL (1) | IL273206A (https=) |
| MA (1) | MA50255A (https=) |
| MX (1) | MX2020002880A (https=) |
| SG (1) | SG11202002298PA (https=) |
| WO (1) | WO2019055677A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201907299XA (en) | 2017-02-08 | 2019-09-27 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| IL268755B2 (en) | 2017-02-20 | 2025-12-01 | Dragonfly Therapeutics Inc | Proteins that bind her2, nkg2d, and cd16 |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| EA202091887A1 (ru) | 2018-02-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры |
| DK3749346T3 (da) | 2018-02-08 | 2024-09-09 | Dragonfly Therapeutics Inc | Antistof variable domænekombinationer rettet mod nkg2d-receptoren |
| WO2019164930A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| WO2019178364A2 (en) * | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| WO2020033630A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| US12378318B2 (en) | 2018-08-08 | 2025-08-05 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and a tumor-associated antigen |
| WO2020081841A1 (en) | 2018-10-19 | 2020-04-23 | Regents Of The University Of Minnesota | Nk engager molecules and methods of use thereof |
| JP7710373B2 (ja) | 2019-02-21 | 2025-07-18 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用 |
| AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| KR20220004751A (ko) | 2019-05-04 | 2022-01-11 | 인히브릭스, 인크. | CLEC12a 결합 폴리펩타이드 및 이의 용도 |
| AR119393A1 (es) * | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | Anticuerpos que se unen a nkg2d |
| MX2022004430A (es) * | 2019-10-15 | 2022-07-19 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), al cumulo de diferenciacion 16 (cd16) y a la tirosina cinasa 3 similar a fms (flt3). |
| CN116234829A (zh) | 2020-01-03 | 2023-06-06 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| MX2022013944A (es) * | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). |
| KR20230008157A (ko) * | 2020-05-06 | 2023-01-13 | 드래곤플라이 쎄라퓨틱스, 인크. | 항체 표적화 clec12a 및 이의 사용 |
| JP2024508894A (ja) | 2021-03-03 | 2024-02-28 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法 |
| PE20241789A1 (es) * | 2021-04-26 | 2024-09-06 | Millennium Pharm Inc | Anticuerpos anti-clec12a y usos de los mismos |
| CN113817065B (zh) * | 2021-09-06 | 2023-04-18 | 深圳市乐土生物医药有限公司 | 一种抗her2的多肽及其用途 |
| CN117106086A (zh) * | 2022-08-09 | 2023-11-24 | 合源康华医药科技(北京)有限公司 | 一种cll1抗体及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040115198A1 (en) * | 2001-02-28 | 2004-06-17 | Fred Hutchinson Cancer Research Center | Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives |
| EP1909832A4 (en) * | 2005-06-29 | 2010-01-13 | Univ Miami | ANTIBODY IMMUNOCELL LIGAND FUSION PROTEIN FOR CANCER THERAPY |
| EP2014680A1 (en) * | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| KR101615935B1 (ko) * | 2007-12-14 | 2016-04-28 | 노보 노르디스크 에이/에스 | 인간 ｎｋｇ2ｄ에 대한 항체 및 그것의 용도 |
| WO2010080124A2 (en) * | 2008-12-18 | 2010-07-15 | Dana-Farber Cancer Institute, Inc. | Nkg2d-fc for immunotherapy |
| US9163090B2 (en) * | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
| EP3470431A1 (en) * | 2012-09-27 | 2019-04-17 | Merus N.V. | Bispecific igg antibodies as t cell engagers |
| WO2017125897A1 (en) * | 2016-01-21 | 2017-07-27 | Novartis Ag | Multispecific molecules targeting cll-1 |
| CN120173123A (zh) * | 2017-02-27 | 2025-06-20 | 蜻蜓疗法股份有限公司 | 靶向caix、ano1、间皮素、trop2、cea或紧密连接蛋白-18.2的多特异性结合蛋白 |
-
2018
- 2018-09-13 SG SG11202002298PA patent/SG11202002298PA/en unknown
- 2018-09-13 MX MX2020002880A patent/MX2020002880A/es unknown
- 2018-09-13 MA MA050255A patent/MA50255A/fr unknown
- 2018-09-13 WO PCT/US2018/050916 patent/WO2019055677A1/en not_active Ceased
- 2018-09-13 EA EA202090718A patent/EA202090718A1/ru unknown
- 2018-09-13 EP EP18856132.8A patent/EP3681532A4/en active Pending
- 2018-09-13 AU AU2018331412A patent/AU2018331412A1/en not_active Abandoned
- 2018-09-13 BR BR112020005078-4A patent/BR112020005078A2/pt not_active Application Discontinuation
- 2018-09-13 US US16/645,613 patent/US20200277384A1/en not_active Abandoned
- 2018-09-13 CN CN201880072887.1A patent/CN111432832A/zh active Pending
- 2018-09-13 CA CA3075857A patent/CA3075857A1/en active Pending
- 2018-09-13 JP JP2020514936A patent/JP2020534269A/ja active Pending
- 2018-09-13 KR KR1020207010605A patent/KR20200051789A/ko not_active Ceased
-
2020
- 2020-03-10 IL IL273206A patent/IL273206A/en unknown
-
2024
- 2024-04-03 JP JP2024060206A patent/JP2024099539A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MA50255A (fr) | 2021-05-26 |
| JP2024099539A (ja) | 2024-07-25 |
| CN111432832A (zh) | 2020-07-17 |
| BR112020005078A2 (pt) | 2020-10-13 |
| SG11202002298PA (en) | 2020-04-29 |
| KR20200051789A (ko) | 2020-05-13 |
| JP2020534269A (ja) | 2020-11-26 |
| CA3075857A1 (en) | 2019-03-21 |
| AU2018331412A1 (en) | 2020-03-26 |
| MX2020002880A (es) | 2020-10-01 |
| US20200277384A1 (en) | 2020-09-03 |
| EP3681532A1 (en) | 2020-07-22 |
| EP3681532A4 (en) | 2021-09-01 |
| WO2019055677A1 (en) | 2019-03-21 |
| IL273206A (en) | 2020-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202090718A1 (ru) | Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1) | |
| EA202091887A1 (ru) | Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры | |
| PE20120549A1 (es) | Proteinas biespecificas de union a antigenos | |
| EA202091888A1 (ru) | Вариабельные домены антител, нацеленные на рецептор nkg2d | |
| EA202192090A1 (ru) | Антигенсвязывающие белки против гамма-цепи рецептора il2 | |
| WO2018057735A8 (en) | Antibodies for siglec-15 and methods of use thereof | |
| EA201992526A1 (ru) | Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения | |
| EA201691482A1 (ru) | Человеческие антитела к pd-1 | |
| EA202092417A1 (ru) | Химерные рецепторы к dll3 и способы их применения | |
| EA202090812A1 (ru) | Новые биспецифические полипептидные комплексы | |
| EA202190542A1 (ru) | Сконструированные биспецифические белки | |
| MX2020012567A (es) | Anticuerpos anti-ox40 y metodos de uso. | |
| EA201990285A1 (ru) | Гетеродимерные иммуноглобулиновые конструкции и способы их получения | |
| MX2022007636A (es) | Anticuerpos biespecificos caninizados y pares de union biespecificos para el tratamiento contra dermatitis atopica. | |
| EA202191785A1 (ru) | Антитела к ctla4 и способы их применения | |
| EA201890296A1 (ru) | Pd-1-связывающие молекулы и способы их применения | |
| EA201690447A1 (ru) | БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬСЯ С gpA33 И CD3, И ИХ ПРИМЕНЕНИЯ | |
| EA201891066A1 (ru) | Антитела к ror1 | |
| PE20221404A1 (es) | Formulaciones farmaceuticas y regimenes de dosificacion para proteinas de union multiespecificas que se unen a her2, nkg2d y cd16 para el tratamiento del cancer | |
| EA201390146A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| PE20241584A1 (es) | Proteinas que se unen a nkg2d, cd16 y baff-r | |
| MX2024001595A (es) | Anticuerpos btla. | |
| EA201491575A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| EA202190235A1 (ru) | Антитела к cd33 и способы их применения | |
| EA202190183A1 (ru) | Антитела к siglec-5 и способы их применения |